The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy endpoints of RTOG 0247: A randomized phase II study of neoadjuvant capecitabine (C) and irinotecan (I) or C and oxaliplatin (O) with concurrent radiation therapy (RT) for locally advanced rectal cancer.
S. J. Wong
Research Funding - Roche
J. Moughan
No relevant relationships to disclose
N. J. Meropol
Consultant or Advisory Role - Genentech
P. R. Anne
No relevant relationships to disclose
L. A. Kachnic
No relevant relationships to disclose
A. Rashid
No relevant relationships to disclose
J. C. Watson
No relevant relationships to disclose
E. P. Mitchell
No relevant relationships to disclose
J. Pollock
No relevant relationships to disclose
M. G. Haddock
No relevant relationships to disclose
B. Erickson
No relevant relationships to disclose
C. G. Willett
No relevant relationships to disclose